Richard is a research and development (R&D) veteran who possesses leadership and product development experience in drug delivery and complex combination products. Richard will oversee development for Lyra’s two product candidates for the treatment of chronic rhinosinusitis, and lead efforts on platform expansion, including next generation technologies that support new indications.
“I am delighted to welcome Bob to Lyra’s executive leadership team, and we expect he will be instrumental in our product development efforts for clinical and commercial success,” said Maria Palasis, Ph.D., president and CEO of Lyra Therapeutics. “We believe that Bob’s depth of knowledge and experience developing combination products will help us efficiently advance our proprietary XTreo platform into new indications, helping to underpin the future growth of our company.”
Richard previously held leadership positions with Anika Therapeutics, C.R. Bard, Boston Scientific, and Johnson & Johnson, where he led R&D organizations through numerous product development initiatives from the concept through to commercialization.
“I believe Lyra is poised to disrupt the treatment paradigm for chronic rhinosinusitis, and I am excited to be joining the company at this time,” said Richard. “I believe that the company’s XTreo platform can be leveraged in a number of new indications, helping to create value for Lyra’s shareholders, while at the same time advancing much-needed treatments for underserved chronic rhinosinusitis patients.”